SAN DIEGO, Feb. 18, 2014 /PRNewswire/ — CUSTOpharm Regulatory Services, today announced that it has acquired Aspire eCTD LLC, an eCTD publishing software company. Aspire eCTD will expand CUSTOpharm Regulatory Services’ portfolio of products and extends our regulatory services by connecting the service and the software as a comprehensive regulatory solution for the pharmaceutical and biotech industries. The two companies have long shared a close relationship since Aspire’s inception and with this acquisition we formally brings the two companies together as one. This acquisition will not result in any changes to the Aspire eCTD product names and will cause no other visible disruptions to the current Aspire eCTD customers. In the coming months Aspire will be enhancing its service offerings for product and support through the support of CUSTOpharm Regulatory Services. This support will enable Aspire eCTD’s growth and development into the leading eCTD software on the market. “Combining the leading regulatory services with the best eCTD product on the market will enable our current and future customers to grow with us and succeed in achieving their goals,” said Fred Defesche, Co-founder and President of CUSTOpharm Regulatory Services. “We stand behind the product and want our customers to be comfortable prior to making the purchase. That is why we offer a 30 day free trial of the program,” said Dave McCleary, Co-founder of CUSTOpharm Regulatory Services.

About the Aspire eCTD product
Aspire eCTD is a windows based electronic submission application. It provides authoring, validation, and publishing features for producing compliant electronic pharmaceutical submissions. Aspire eCTD was designed to be a product that was powerful yet simple to use. With Aspire eCTD, you will be able to process submissions more easily and quickly than ever before. For more information, please visit http://www.aspireectd.com.

About CUSTOpharm Regulatory Services, Inc.
CUSTOpharm Regulatory Services is a leading provider of regulatory affairs services. CUSTOpharm Regulatory Services has been a pioneer in the ever changing regulatory landscape by being one of the first companies to transition to eCTD submissions in 2004 and moving to the gateway in 2008. Services provided include CMC writing, publishing of eCTD submissions and SPL generation for the pharmaceutical and biotech industries. We have filed more than 200 original applications and file more than 100 submissions per year. For more information, please visit http://www.custopharm.com.

Media Contacts:

Fred Defesche
(760) 481-7811
fdefesche@custopharm.com

SOURCE CUSTOpharm Regulatory Services, Inc.